Literature DB >> 35078927

Benefit and risk of intravenous alteplase in patients with acute large vessel occlusion stroke and low ASPECTS.

Gabriel Broocks1, Rosalie McDonough2, Matthias Bechstein2, Uta Hanning2, Caspar Brekenfeld2, Fabian Flottmann2, Helge Kniep2, Marie Teresa Nawka2, Milani Deb-Chatterji3, Götz Thomalla3, Peter Sporns2,4, Leonard Ll Yeo5, Benjamin Yq Tan5, Anil Gopinathan5, Andreas Kastrup6, Maria Politi7, Panagiotis Papanagiotou7,8, Andre Kemmling9, Jens Fiehler2, Lukas Meyer2.   

Abstract

BACKGROUND: The benefit of best medical treatment including intravenous alteplase (IVT) before mechanical thrombectomy (MT) in patients with acute ischemic stroke and extensive early ischemic changes on baseline CT remains uncertain. The purpose of this study was to evaluate the benefit of IVT for patients with low ASPECTS (Alberta Stroke Programme Early CT Score) compared with patients with or without MT.
METHODS: This multicenter study pooled consecutive patients with anterior circulation acute stroke and ASPECTS≤5 to analyze the impact of IVT on functional outcome, and to compare bridging IVT with direct MT. Functional endpoints were the rates of good (modified Rankin Scale (mRS) score ≤2) and very poor (mRS ≥5) outcome at day 90. Safety endpoint was the occurrence of symptomatic intracranial hemorrhage (sICH).
RESULTS: 429 patients were included. 290 (68%) received IVT and 168 (39%) underwent MT. The rate of good functional outcome was 14.4% (95% CI 7.1% to 21.8%) for patients who received bridging IVT and 24.4% (95% CI 16.5% to 32.2%) for those who underwent direct MT. The rate of sICH was significantly higher in patients with bridging IVT compared with direct MT (17.8% vs 6.4%, p=0.004). In multivariable logistic regression analysis, IVT was significantly associated with very poor outcome (OR 2.22, 95% CI 1.05 to 4.73, p=0.04) and sICH (OR 3.44, 95% CI 1.18 to 10.07, p=0.02). Successful recanalization, age, and ASPECTS were associated with good functional outcome.
CONCLUSIONS: Bridging IVT in patients with low ASPECTS was associated with very poor functional outcome and an increased risk of sICH. The benefit of this treatment should therefore be carefully weighed in such scenarios. Further randomized controlled trials are required to validate our findings. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  brain; stroke; thrombectomy; thrombolysis

Year:  2022        PMID: 35078927     DOI: 10.1136/neurintsurg-2021-017986

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  1 in total

1.  Editorial: Mechanisms, Measurement, and Management of Vasogenic Edema After Stroke.

Authors:  Gabriel Broocks; Jens Minnerup; Shervin Kamalian; Andre Kemmling
Journal:  Front Neurol       Date:  2022-02-24       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.